CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute
Tharageswari Srinivasan1, Nabhajit Mallik1, Man Updesh Singh Sachdeva1
1Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objectives:
To evaluate the utility of CD48 as a marker to distinguish T-lymphoblasts from mature T cells and NK cells in T-lineage acute lymphoblastic leukemia (T-ALL) for measurable residual disease (MRD) detection by flow cytometry.
Methods:
CD48 expression was assessed in T-lymphoblasts and mature T cells from 51 diagnostic T-ALL samples and 84 post-therapy samples. Normalized median fluorescence intensity (nMFI) of CD48 was calculated as the ratio of MFI in the population of interest to that in mature B cells.
Results:
At diagnosis, the median CD48 nMFI in T-lymphoblasts was significantly lower (0.14) compared to mature T cells (1.29) (p < 0.0001). In MRD-positive post-therapy samples, T-lymphoblasts had a lower nMFI (0.22) than mature T cells (1.4), NK cells (1.06), and γδ T cells (1.09) (p < 0.0001).
Conclusion:
CD48 demonstrates consistent under-expression in T-lymphoblasts compared to mature T cells and NK cell cells, supporting its use as a reliable and informative marker for MRD detection in T-ALL. Its inclusion would enhance the accuracy of flow cytometry-based MRD panels.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016